Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for XNCR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 1.031M
March 31, 2026 0.95M
December 31, 2025 4.596M
September 30, 2025 0.00
June 30, 2025 0.662M
March 31, 2025 2.974M
December 31, 2024 4.431M
September 30, 2024 187.74M
June 30, 2024 -0.943M
March 31, 2024 0.186M
December 31, 2023 22.48M
September 30, 2023 0.356M
June 30, 2023 1.921M
March 31, 2023 0.922M
December 31, 2022 1.171M
September 30, 2022 1.287M
June 30, 2022 2.513M
March 31, 2022 0.731M
December 31, 2021 32.63M
September 30, 2021 3.229M
June 30, 2021 1.84M
March 31, 2021 5.339M
December 31, 2020 9.587M
September 30, 2020 2.986M
June 30, 2020 4.00M
Date Value
March 31, 2020 1.471M
December 31, 2019 2.973M
September 30, 2019 3.049M
June 30, 2019 3.973M
March 31, 2019 0.667M
December 31, 2018 1.165M
September 30, 2018 4.153M
June 30, 2018 2.308M
March 31, 2018 246.62M
December 31, 2017 0.621M
September 30, 2017 0.99M
June 30, 2017 1.096M
March 31, 2017 1.026M
December 31, 2016 119.80M
September 30, 2016 0.501M
June 30, 2016 0.473M
March 31, 2016 0.20M
December 31, 2015 0.387M
September 30, 2015 0.114M
June 30, 2015 0.33M
March 31, 2015 115.55M
December 31, 2014 0.177M
September 30, 2014 -0.002M
June 30, 2014 0.131M
March 31, 2014 0.002M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
UroGen Pharma Ltd. 2.186M
MeiraGTx Holdings Plc 133.89M
Regeneron Pharmaceuticals, Inc. -1.225B
Ironwood Pharmaceuticals, Inc. -199.70M
MacroGenics, Inc. 60.17M